Investor's Business Daily on MSN
Amgen tops buy zone on positive 2026 outlook amid sharpening obesity focus
Amgen is running a number of studies of its obesity drug, MariTide.
Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果